PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: mic_mcgoldrick@merck.com.\', \'Sanofi Pasteur, France. Electronic address: Thierry.Gastineau@sanofi.com.\', \'AstraZeneca, United Kingdom. Electronic address: diane.wilkinson@astrazeneca.com.\', \'GSK, United Kingdom. Electronic address: cristiana.x.campa@gsk.com.\', \'GSK, United Kingdom. Electronic address: norbert.de-clercq@gsk.com.\', \'GSK, United Kingdom. Electronic address: andrea.x.mallia-milanes@gsk.com.\', \'GSK, United Kingdom. Electronic address: olivier.c.germay@gsk.com.\', \'GSK, United Kingdom. Electronic address: jyothsna.x.krishnan@gsk.com.\', \'Janssen, Belgium. Electronic address: mvanooi@its.jnj.com.\', \'Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: michael_thien@merck.com.\', \'Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: peter_mlynarczyk@merck.com.\', \'Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: ed.saltus@merck.com.\', \'Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: florence.wauters@merck.com.\', \'Sanofi Pasteur, France. Electronic address: Philippe.Juvin@sanofi.com.\', \'Sanofi Pasteur, France. Electronic address: Didier.Clenet@sanofi.com.\', \'Sanofi Pasteur, France. Electronic address: Ana.Basso@sanofi.com.\', \'QRB Consultants Sàrl, Switzerland. Electronic address: dellepianen@outlook.com.\', \'DCVMN International, Switzerland. Electronic address: s.pagliusi@dcvmn.net.\', \'Bio-Manguinhos / Fiocruz, Brazil. Electronic address: Monique.moraes@bio.fiocruz.br.\', \'Bharat Biotech International Ltd, India. Electronic address: venkatraman2065@bharatbiotech.com.\', \'Cadila Healthcare Limited (Zydus Cadila), India. Electronic address: samirdesai@zyduscadila.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0264-410X(21)01646-710.1016/j.vaccine.2021.12.038
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 35180994
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35180994>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35180994>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all